Lung Pathway Group Metrics

Stephen Scott
Senior Cancer Information Analyst
Metrics Collated for Lung pathway group

- Cancer Waiting Times Data
  - Sourced from Open Exeter

- % of cases staged
  - Sourced from TCR

- LUCADA data completeness and surgical resection rates
  - Published on LUCADA website

- National Cancer Patient Experience survey results
  - Published on quality health website

- % emergency presentation
  - Routes of diagnosis work by NCIN

- Peer Review scores
  - CQUINS public website

- Incidence/mortality/survival
  - National Cancer Data Repository
    (source from cancer registry data)
Key issues to consider

- Cancer data quality across London a major issue
- Data improvement work on-going since May 2012 in partnership with TCR. Particularly around staging completeness
- LCA providers are the source of all the data shown
- Most is publicly available to patients and all available to commissioners
- New national cancer dataset (COSD) commenced implementation in January 2013
- Metrics to be used for informing pathway group on potential areas for service improvement and demonstrating effects of change, as well as being made available to local services for use locally.
<table>
  <thead>
    <tr>
      <th colspan="4" align="center"><h2>Lung pathway group metrics</h2></th>
    </tr>
  </thead>
  <tbody>
    <tr align="center">
      <td colspan="4" align="center"><h3>Last updated 17<sup>th</sup> January 2013</h3></td>
    </tr>
    <tr align="center">
      <td colspan="4" align="center"><h3><a>Log of updates</a></h3></td>
    </tr>
    <tr>
      <td align="center" width="25%"><strong>Cancer Waiting Times</strong></td>
      <td align="center" width="25%"><strong>Prevention/Early diagnosis</strong></td>
      <td align="center" width="25%"><strong>Incidence/mortality/survival (28)</strong></td>
      <td align="center" width="25%"><strong>Metrics in development</strong></td>
    </tr>
    <tr>
      <td align="center" width="25%"><ul>
          <li>1.1 2 week wait GP urgent referral to 1<sup>st</sup> seen</li>
          <li>1.2 31 day decision to treat to 1<sup>st</sup> treatment</li>
          <li>1.3 31 day subsequent surgery</li>
          <li>1.4 31 day subsequent drugs</li>
          <li>1.5 31 day subsequent radiotherapy</li>
          <li>1.6 62 day GP urgent referral to 1<sup>st</sup> treatment</li>
        </ul></td>
      <td align="center" width="25%"><ul>
          <li>4.1 % emergency presentation</li>
        </ul></td>
      <td align="center" width="25%"><ul>
          <li>8.1 Incidence rates</li>
          <li>Trachea, Bronchus and Lung (C33-34)</li>
          <li>Mesothelioma (C45)</li>
          <li>8.2 Mortality rates</li>
          <li>Trachea, Bronchus and Lung (C33-34)</li>
          <li>Mesothelioma (C45)</li>
        </ul></td>
      <td align="center" width="25%">Metrics in development</td>
    </tr>
    <tr>
      <td align="center" width="25%"><strong>Data collection (2)</strong></td>
      <td align="center" width="25%"><strong>Diagnosis</strong></td>
      <td align="center" width="25%"><strong>Treatment</strong></td>
      <td align="center" width="25%"><strong>Peer review (2)</strong></td>
    </tr>
    <tr>
      <td align="center" width="25%"><ul>
          <li>2.1 % of cases fully staged in MDT feed to TCR</li>
          <li>2.2 LUCADA data completeness</li>
        </ul></td>
      <td align="center" width="25%"><strong>5.1 Lung cancer resection rates - overall</strong></td>
      <td align="center" width="25%"><ul>
          <li>5.2 Lung cancer resection rates - NSCLC – Total</li>
          <li>5.3 Lung cancer resection rates - NSCLC – Stage 1 & 2</li>
        </ul></td>
      <td align="center" width="25%"><ul>
          <li>7.1 Peer review compliance network measures</li>
          <li>7.2 Peer review compliance – trust measures</li>
        </ul></td>
    </tr>
    <tr>
      <td align="center" width="25%"><strong>Patient experience (2)</strong></td>
      <td align="center" width="25%"><strong>Prevention/Early diagnosis</strong></td>
      <td align="center" width="25%"><strong>Incidence/mortality/survival (28)</strong></td>
      <td align="center" width="25%">Metrics in development</td>
    </tr>
    <tr>
      <td align="center" width="25%"><ul>
          <li>3.1 NCPS 020 - Patient given name of the CP in charge</li>
          <li>3.2 NCPS 067 - Patient given right amount of information about condition and treatment</li>
        </ul></td>
      <td align="center" width="25%"><strong>5.1 Lung cancer resection rates - overall</strong></td>
      <td align="center" width="25%"><ul>
          <li>8.1 Incidence rates</li>
          <li>Trachea, Bronchus and Lung (C33-34)</li>
          <li>Mesothelioma (C45)</li>
          <li>8.2 Mortality rates</li>
          <li>Trachea, Bronchus and Lung (C33-34)</li>
          <li>Mesothelioma (C45)</li>
        </ul></td>
      <td align="center" width="25%">Metrics in development</td>
    </tr>
  </tbody>
</table>
62 day GP referral to 1st treatment (1.6)
Quarter 2 – 2012/13

- 62 day target a challenge for Lung both within the LCA (78.5%) and England overall (80.3%)
2.1. % of cases fully stage in MDT feed to Thames Cancer Registry - Lung (C34) – Quarter 2 2012/13

Overall – highest proportion of cases staged for Lung within LCA
- 60.4% Fully staged
- 8.2% Partially staged
- 31.4% No stage

Significant differences between trusts – 30-91% fully staged

Source: Thames Cancer Registry – Q2 2012/13 report
## 2.2. % of cases submitted to LUCADA

<table>
<thead>
<tr>
<th>Trust Name</th>
<th>Expected number of cases</th>
<th>Actual number of cases</th>
<th>% of expected</th>
</tr>
</thead>
<tbody>
<tr>
<td>West Middlesex University NHS Trust (RFW)</td>
<td>70</td>
<td>94</td>
<td>134.3%</td>
</tr>
<tr>
<td>Ealing Hospital NHS Trust (RC3)</td>
<td>75</td>
<td>90</td>
<td>120.0%</td>
</tr>
<tr>
<td>Croydon Health Services NHS Trust (RJ6)</td>
<td>132</td>
<td>144</td>
<td>109.1%</td>
</tr>
<tr>
<td>The Hillingdon NHS Foundation Trust (RAS)</td>
<td>100</td>
<td>107</td>
<td>107.0%</td>
</tr>
<tr>
<td>South London Healthcare NHS Trust (RYQ)</td>
<td>370</td>
<td>364</td>
<td>98.4%</td>
</tr>
<tr>
<td>East and North Herforshire NHS Trust (RWH)</td>
<td>206</td>
<td>202</td>
<td>98.1%</td>
</tr>
<tr>
<td>Kings College Hospital NHS Foundation Trust (RJZ)</td>
<td>114</td>
<td>109</td>
<td>95.6%</td>
</tr>
<tr>
<td>Lewisham Healthcare NHS Trust (RJ2)</td>
<td>116</td>
<td>108</td>
<td>93.1%</td>
</tr>
<tr>
<td>North West London Hospitals NHS Trust (RV8)</td>
<td>100</td>
<td>88</td>
<td>88.0%</td>
</tr>
<tr>
<td>Epsom and St Helier NHS Trust (RVR)</td>
<td>245</td>
<td>199</td>
<td>81.2%</td>
</tr>
<tr>
<td>Imperial College Healthcare NHS Trust (RYJ)</td>
<td>289</td>
<td>234</td>
<td>81.0%</td>
</tr>
<tr>
<td>Kingston Hospital NHS Trust (RAX)</td>
<td>159</td>
<td>117</td>
<td>73.6%</td>
</tr>
<tr>
<td>Chelsea and Westminster NHS Foundation Trust (RQM)</td>
<td>80</td>
<td>58</td>
<td>72.5%</td>
</tr>
<tr>
<td>St Georges Healthcare NHS Trust (RJ7)</td>
<td>239</td>
<td>173</td>
<td>72.4%</td>
</tr>
<tr>
<td>Guys and St Thomas’ NHS Foundation Trust (RJ1)</td>
<td>273</td>
<td>121</td>
<td>44.3%</td>
</tr>
<tr>
<td>The Royal Brompton and Harefield NHS Foundation Trust (RT3)</td>
<td>148</td>
<td>19</td>
<td>n/a</td>
</tr>
<tr>
<td>The Royal Marsden NHS Foundation Trust (RPY)</td>
<td>n/a</td>
<td>17</td>
<td>n/a</td>
</tr>
<tr>
<td><strong>LCA - overall</strong></td>
<td><strong>2568</strong></td>
<td><strong>2208</strong></td>
<td><strong>86.0%</strong></td>
</tr>
</tbody>
</table>

**Key:**
- Green - >75% of expected cases
- Orange 50-70% of expected cases
- Red <50% of expected cases
- Blue – Tertiary centre so benchmarking not appropriate

- LUCADA has the best completeness of the National Audits across the LCA
- There are known issues with the benchmarks set Nationally.
5.1 – Lung cancer resection rates - overall

- This data is in public domain (LUCADA website)
- Data should be used with caution (i.e. is the data accurate)
- LUCADA allocates cases on diagnosing trust, not treating centre
- However could be errors with diagnosing trust (i.e. treating trust rather than diagnosing trust being recorded)
- Highlights importance of ensuring data is accurate as well as complete
### 8.3. Survival Rates – Age standardised -3 year rolling

**Cancers of Trachea, Bronchus and Lung (C33-34)**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Value (%) LCI</td>
<td>UCI</td>
<td>Value (%) LCI</td>
<td>UCI</td>
</tr>
<tr>
<td><strong>North West London Cancer Network</strong></td>
<td>32.94 (30.77, 35.12)</td>
<td>15.97 (14.21, 17.72)</td>
<td>12.77 (11.07, 14.47)</td>
<td>9.78 (8.05, 11.51)</td>
</tr>
<tr>
<td><strong>South East London Cancer Network</strong></td>
<td>32.90 (30.85, 34.95)</td>
<td>12.14 (10.65, 13.64)</td>
<td>7.84 (6.54, 9.05)</td>
<td>5.22 (4.00, 6.44)</td>
</tr>
<tr>
<td><strong>South West London Cancer Network</strong></td>
<td>37.07 (34.80, 39.35)</td>
<td>14.18 (12.46, 15.91)</td>
<td>9.98 (8.40, 11.56)</td>
<td>8.91 (7.23, 10.59)</td>
</tr>
<tr>
<td><strong>London (SHA)</strong></td>
<td>33.19 (32.18, 34.19)</td>
<td>13.45 (12.69, 14.21)</td>
<td>9.88 (9.18, 10.59)</td>
<td>7.31 (6.62, 8.00)</td>
</tr>
<tr>
<td><strong>England</strong></td>
<td>30.38 (30.06, 30.71)</td>
<td>11.54 (11.30, 11.78)</td>
<td>8.35 (8.13, 8.57)</td>
<td>5.82 (5.61, 6.04)</td>
</tr>
</tbody>
</table>

*Source – NCIS – National Cancer Intelligence Service*

*Benchmarking used –*

*Green- Value 95% LCI more than England 95% UCI (i.e. significantly better than England average)*

*Red- Value 95% UCI less than England 95% LCI (i.e. significantly worse than England average)*

- **1 year survival** – higher than England average in NWL, SWL & NWL
- **3 year survival** – higher than England average in NWL & SWL
- **5 year survival** – higher than England average in NWL
- **10 year survival** – higher than England average in NWL & SWL
Next Steps

- Metrics refreshed once COSD data submitted to TCR (22 site specific items for Lung)

<table>
<thead>
<tr>
<th>General</th>
<th>Pathology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Procedure date (CT, PET and Bronchoscopy)</td>
<td>Investigation result date</td>
</tr>
<tr>
<td>Scan performance? (CT/PET and Bronchoscopy)</td>
<td>Service Report Identifier</td>
</tr>
<tr>
<td>FEV1 Percentage and absolute value</td>
<td>Proximity to carina (&lt; 20mm or &gt; 20mm)</td>
</tr>
<tr>
<td>Smoking status</td>
<td>Extent of atelectasis</td>
</tr>
<tr>
<td>Mediastinal sampling indicator</td>
<td>Pericardial invasion, Diaphragm invasion (Y/N), Heart invasion (Y/N), Malignant pleural effusion (Y/N)</td>
</tr>
<tr>
<td>Epidermal growth factor receptor mutational status</td>
<td>Satellite tumour nodules location</td>
</tr>
</tbody>
</table>

- Pathway group to agree additional data collection by Trusts if required
Questions?